2015 Fiscal Year Final Research Report
Combination therapy of fish oil and pioglitazone on the adverse effect caused by pioglitazone administration
| Project/Area Number |
25504012
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Integrated Nutrition Science
|
|---|
| Research Institution | Josai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 魚油 / ピオグリタゾン / 皮下脂肪蓄積 / 膵β細胞 / 最小有効量 |
|---|
| Outline of Final Research Achievements |
Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. We demonstrated that the combination of pioglitazone and fish oil may prevent the adverse effects of pioglitazone on promoting excessive body weight gain and subcutaneous fat accumulation. And, this study showed that fish oil and pioglitazone effectively prevented hypertrophy of the pancreatic islets and apoptosis-induced cell death through increased insulin sensitivity and decreased ER stress. The reduction of β-cell dysfunction by fish oil and pioglitazone may be leaded to the suppression of systemic oxidative stress because of decreased visceral fat levels.
The results suggest that the combination of pioglitazone and fish oil has particular efficacy in diabetic patients with fatty liver and adipose tissue inflammation.
|
| Free Research Field |
脂質栄養
|
